Floatz Rating
D30/100
Confidence
Indicative
Sponsor
National Taiwan University Hospital
Modality
mixture
Development Phase
N/A
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00166868CT.gov Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia After the Kasai Portoenterostomy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Biliary Atresia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Neomycin (this asset) | National Taiwan University Hospital | N/A | D · 30 |
| Meloxidolor | Yonsei University | P4 | BB |
| Pentoxifylline | Baylor College of Medicine | P2 | CCC |
| Vancomycin | Sacramento Pediatric Gastroenterology | P1 | CC |
| Lactobacillus Casei Rhamnosus (Lcr35) | National Taiwan University Hospital | N/A | D |
| Imipenem | Children's Hospital of Fudan University | N/A | D |
| Trimethoprim | Children's Hospital of Fudan University | N/A | D |
| Ursodeoxycholic Acid | Children's Hospital of Fudan University | N/A | D |
| Meropenem | Children's Hospital of Fudan University | N/A | D |
+3 more in the Biliary Atresia cohort
Other indications for Neomycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Carcinoma | — | P4 | B · 63 |
| Colorectal Neoplasm | — | P4 | B · 63 |
| Colorectal Cancer | — | P4 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Neomycin in Biliary Atresia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/neomycin-biliary-atresia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →